{
 "as_of": "2026-11-08",
 "cmr": "us-cm-kg/NASDAQ/NAMS",
 "fence": "The page is the record's research on the issuer — no analyst, no rating, no view.",
 "markdown": "The page is the record's research on the issuer — no analyst, no rating, no view.\n\n# NewAmsterdam Pharma Co N.V. (NASDAQ: NAMS) — research page\n\nAs of 2026-11-08 · us-cm-kg · record version 1\n\n## Identity and listing\n\nThe issuer is NewAmsterdam Pharma Co N.V., listed on NASDAQ under ticker NAMS, with ISIN USN625091095. The LEI is not on the record (no GLEIF record with the exact legal name in jurisdiction US-P7). The security type is Corporate, the segment is not on the record, the sector is 2834 Pharmaceutical Preparations, and the jurisdiction is Netherlands. The issuer is listed and not halted.\n\n## The disclosure read\n\nThe record holds 81 filings in the twelve months from 2025-11-08 to 2026-11-08, across 53 filing days. The median gap between filing days is 4.0 days. The latest filing is dated 2026-11-05, a regulatory_filing, 3 days before the record date. The NASDAQ median for filings is 52, the median cadence gap is 6.0 days, and the median latency is 5.0 days. The sector median for filings is 63.0, the median cadence gap is 6.0 days, and the median latency is 4.0 days.\n\n## Auditor\n\nThe auditor is not on the record (no dei:AuditorName tag on the latest annual report cover; foreign private issuers and older filings carry none). The auditor location is not on the record. The record holds no auditor changes.\n\n## Events and halts\n\nThe record holds no listing, delisting or name change lines. The domicile change is not on the record (EDGAR states no dated change of state of incorporation on a filing line). The segment move is not on the record (the exchanges' tier transfers are not EDGAR filings). The halt flag is listed, not halted.\n\n## Orderability\n\nThe outcome is not determinable: the chapter's orderability section carries no client_categories, so the outcome cannot name its client category. The rule version is acm-68000/us/reasonable-basis-suitability-finra-rule-2111/r1, with the chapter as of 2026-11-04.\n\n## Coverage\n\nThe issuer's own investor-relations page names 17 research houses: BMO Capital Markets, Cantor Fitzgerald & Co., Citi, Goldman Sachs & Co. LLC, Guggenheim Securities, LLC, H.C. Wainwright, Jefferies, Leerink Partners, Needham & Company, LLC, Piper Sandler & Co, RBC Capital Markets, Stifel, TD Cowen, Truist Securities, Van Lanschot Kempen, Wells Fargo, and William Blair & Company.\n\n## Open research\n\nThe record holds no openly published research notes. None was found.\n\n## Licensed\n\nLicensed research: none loaded. A licensed row is served only to an agent whose firm holds that licence (licensor, entitlement). No licensed row is loaded.\n\n## As-of depth\n\nThe issuer's years sealed are 2022, 2023, 2024, 2025 and 2026. The market's earliest sealed date is 2021-01-04. The live record began on 2026-09-12. The market's vintage is sealed.\n\n## Sources\n\n8 source pages are named on this page; every value above carries its own source page and read date in the numbers.\n\n- https://www.sec.gov/files/company_tickers_exchange.json (identity.exchange)\n- https://www.sec.gov/data-research/sec-markets-data/fails-deliver-data (identity.isin)\n- https://data.sec.gov/submissions/CIK0001936258.json (identity.jurisdiction)\n- https://mcp.us-cm-kg.ai/events/NASDAQ/NAMS (the disclosure lines)\n- https://www.nasdaqtrader.com/rss.aspx?feed=tradehalts (the halt flag)\n- https://mcp.us-cm-kg.ai/book/aio.json (the orderability chapter)\n- https://ir.newamsterdampharma.com/stock-information/analyst-coverage (coverage)\n- https://mcp.us-cm-kg.ai/record/NASDAQ/NAMS (the record)\n",
 "market": "US",
 "node": "us-cm-kg",
 "numbers": {
  "as_of_depth": {
   "issuer_years_sealed": [
    "2022",
    "2023",
    "2024",
    "2025",
    "2026"
   ],
   "live_record_began": "2026-09-12",
   "node_history_from": "2021-01-04",
   "node_years_sealed": [
    "2021",
    "2022",
    "2023",
    "2024",
    "2025",
    "2026"
   ],
   "record_version": 1,
   "sealed": true
  },
  "auditor": {
   "auditor": {
    "market": "US",
    "reason": "no dei:AuditorName tag on the latest annual report cover (foreign private issuers and older filings carry none)",
    "state": "not_on_record"
   },
   "auditor_firm_id": {
    "market": "US",
    "state": "not_on_record"
   },
   "auditor_location": {
    "market": "US",
    "state": "not_on_record"
   },
   "changes": []
  },
  "cmr": "us-cm-kg/NASDAQ/NAMS",
  "coverage": {
   "count": 17,
   "houses": [
    {
     "analyst": "Conor Mackay",
     "house": "BMO Capital Markets",
     "read_by": "issuer IR page, fetched by this rail; each house name read on the page",
     "read_date": "2026-11-11",
     "source": "https://ir.newamsterdampharma.com/stock-information/analyst-coverage",
     "state": "sourced"
    },
    {
     "analyst": "Steve Seedhouse",
     "house": "Cantor Fitzgerald & Co.",
     "read_by": "issuer IR page, fetched by this rail; each house name read on the page",
     "read_date": "2026-11-11",
     "source": "https://ir.newamsterdampharma.com/stock-information/analyst-coverage",
     "state": "sourced"
    },
    {
     "analyst": "Geoff Meacham",
     "house": "Citi",
     "read_by": "issuer IR page, fetched by this rail; each house name read on the page",
     "read_date": "2026-11-11",
     "source": "https://ir.newamsterdampharma.com/stock-information/analyst-coverage",
     "state": "sourced"
    },
    {
     "analyst": "Asad Haider",
     "house": "Goldman Sachs & Co. LLC",
     "read_by": "issuer IR page, fetched by this rail; each house name read on the page",
     "read_date": "2026-11-11",
     "source": "https://ir.newamsterdampharma.com/stock-information/analyst-coverage",
     "state": "sourced"
    },
    {
     "analyst": "Debjit Chattopadhyay, Ph.D.",
     "house": "Guggenheim Securities, LLC",
     "read_by": "issuer IR page, fetched by this rail; each house name read on the page",
     "read_date": "2026-11-11",
     "source": "https://ir.newamsterdampharma.com/stock-information/analyst-coverage",
     "state": "sourced"
    },
    {
     "analyst": "Lander Egana Gorrono, Ph.D.",
     "house": "H.C. Wainwright",
     "read_by": "issuer IR page, fetched by this rail; each house name read on the page",
     "read_date": "2026-11-11",
     "source": "https://ir.newamsterdampharma.com/stock-information/analyst-coverage",
     "state": "sourced"
    },
    {
     "analyst": "Dennis Ding",
     "house": "Jefferies",
     "read_by": "issuer IR page, fetched by this rail; each house name read on the page",
     "read_date": "2026-11-11",
     "source": "https://ir.newamsterdampharma.com/stock-information/analyst-coverage",
     "state": "sourced"
    },
    {
     "analyst": "Roanna Ruiz, Ph.D.",
     "house": "Leerink Partners",
     "read_by": "issuer IR page, fetched by this rail; each house name read on the page",
     "read_date": "2026-11-11",
     "source": "https://ir.newamsterdampharma.com/stock-information/analyst-coverage",
     "state": "sourced"
    },
    {
     "analyst": "Serge Belanger",
     "house": "Needham & Company, LLC",
     "read_by": "issuer IR page, fetched by this rail; each house name read on the page",
     "read_date": "2026-11-11",
     "source": "https://ir.newamsterdampharma.com/stock-information/analyst-coverage",
     "state": "sourced"
    },
    {
     "analyst": "Yasmeen Rahimi, Ph.D.",
     "house": "Piper Sandler & Co",
     "read_by": "issuer IR page, fetched by this rail; each house name read on the page",
     "read_date": "2026-11-11",
     "source": "https://ir.newamsterdampharma.com/stock-information/analyst-coverage",
     "state": "sourced"
    },
    {
     "analyst": "Leonid Timashev, Ph.D.",
     "house": "RBC Capital Markets",
     "read_by": "issuer IR page, fetched by this rail; each house name read on the page",
     "read_date": "2026-11-11",
     "source": "https://ir.newamsterdampharma.com/stock-information/analyst-coverage",
     "state": "sourced"
    },
    {
     "analyst": "James Condulis",
     "house": "Stifel",
     "read_by": "issuer IR page, fetched by this rail; each house name read on the page",
     "read_date": "2026-11-11",
     "source": "https://ir.newamsterdampharma.com/stock-information/analyst-coverage",
     "state": "sourced"
    },
    {
     "analyst": "Tyler van Buren",
     "house": "TD Cowen",
     "read_by": "issuer IR page, fetched by this rail; each house name read on the page",
     "read_date": "2026-11-11",
     "source": "https://ir.newamsterdampharma.com/stock-information/analyst-coverage",
     "state": "sourced"
    },
    {
     "analyst": "Srikripa Devarakonda, Ph.D.",
     "house": "Truist Securities",
     "read_by": "issuer IR page, fetched by this rail; each house name read on the page",
     "read_date": "2026-11-11",
     "source": "https://ir.newamsterdampharma.com/stock-information/analyst-coverage",
     "state": "sourced"
    },
    {
     "analyst": "Sebastiaan van der Schoot, Ph.D.",
     "house": "Van Lanschot Kempen",
     "read_by": "issuer IR page, fetched by this rail; each house name read on the page",
     "read_date": "2026-11-11",
     "source": "https://ir.newamsterdampharma.com/stock-information/analyst-coverage",
     "state": "sourced"
    },
    {
     "analyst": "Yanan Zhu",
     "house": "Wells Fargo",
     "read_by": "issuer IR page, fetched by this rail; each house name read on the page",
     "read_date": "2026-11-11",
     "source": "https://ir.newamsterdampharma.com/stock-information/analyst-coverage",
     "state": "sourced"
    },
    {
     "analyst": "Matthew Phipps, Ph.D.",
     "house": "William Blair & Company",
     "read_by": "issuer IR page, fetched by this rail; each house name read on the page",
     "read_date": "2026-11-11",
     "source": "https://ir.newamsterdampharma.com/stock-information/analyst-coverage",
     "state": "sourced"
    }
   ],
   "pages_checked": [
    {
     "page": "https://ir.newamsterdampharma.com/stock-information/analyst-coverage",
     "result": "read: 17 of 34 named houses found on the page"
    }
   ],
   "read_by": "Perplexity sonar (search) · page read by this rail",
   "read_date": "2026-11-11",
   "since": "not stated on the page read",
   "state": "found"
  },
  "disclosure": {
   "against": {
    "exchange": {
     "issuers": 4359,
     "median_cadence_gap_days": 6,
     "median_filings": 52,
     "median_latency_days": 5,
     "name": "NASDAQ"
    },
    "sector": {
     "issuers": 526,
     "median_cadence_gap_days": 6,
     "median_filings": 63,
     "median_latency_days": 4,
     "name": "2834 Pharmaceutical Preparations"
    }
   },
   "by_type": {
    "ad_hoc": 1,
    "agm_egm": 2,
    "corporate_news": 4,
    "director_change": 5,
    "directors_dealings": 29,
    "regulatory_filing": 32,
    "results": 8
   },
   "cadence_median_gap_days": 4,
   "filing_days": 53,
   "filings": 81,
   "latency_days": 3,
   "latest": [
    {
     "category": "SCHEDULE 13G/A",
     "date": "2026-11-05",
     "source": "https://www.sec.gov/Archives/edgar/data/1936258/000031506626002799/xslSCHEDULE_13G_X02/primary_doc.xml",
     "title": "SCHEDULE 13G/A",
     "type": "regulatory_filing"
    },
    {
     "category": "10-Q",
     "date": "2026-11-04",
     "source": "https://www.sec.gov/Archives/edgar/data/1936258/000119312526446228/nams-20260930.htm",
     "title": "10-Q — 10-Q",
     "type": "results"
    },
    {
     "category": "8-K",
     "date": "2026-11-04",
     "source": "https://www.sec.gov/Archives/edgar/data/1936258/000119312526446219/nams-20261104.htm",
     "title": "8-K — 8-K (items 9.01)",
     "type": "ad_hoc"
    },
    {
     "category": "4",
     "date": "2026-10-02",
     "source": "https://www.sec.gov/Archives/edgar/data/1936258/000119312526412431/xslF345X06/ownership.xml",
     "title": "4 — 4",
     "type": "directors_dealings"
    },
    {
     "category": "8-K",
     "date": "2026-09-29",
     "source": "https://www.sec.gov/Archives/edgar/data/1936258/000119312526406063/nams-20260929.htm",
     "title": "8-K — 8-K (items 8.01,9.01)",
     "type": "corporate_news"
    }
   ],
   "latest_filing_date": "2026-11-05",
   "read": "the node's event lines (list_events_since), as get_filings serves them",
   "source": "https://mcp.us-cm-kg.ai/events/NASDAQ/NAMS",
   "window": {
    "from": "2025-11-08",
    "to": "2026-11-08"
   }
  },
  "identity": {
   "exchange": {
    "read_by": "EDGAR company_tickers_exchange.json (SEC list of exchange-listed filers)",
    "read_date": "2026-11-08",
    "read_date_basis": "the record version as_of",
    "source": "https://www.sec.gov/files/company_tickers_exchange.json",
    "state": "sourced",
    "value": "NASDAQ"
   },
   "isin": {
    "read_by": "SEC Fails-to-Deliver data (CUSIP for the symbol) · ISIN = US + CUSIP + ISO 6166 check digit",
    "read_date": "2026-10-07",
    "read_date_basis": "last_seen",
    "source": "https://www.sec.gov/data-research/sec-markets-data/fails-deliver-data",
    "state": "sourced",
    "value": "USN625091095"
   },
   "jurisdiction": {
    "read_by": "EDGAR submissions API (issuer header as filed) (stateOfIncorporation)",
    "read_date": "2026-11-08",
    "read_date_basis": "the record version as_of",
    "source": "https://data.sec.gov/submissions/CIK0001936258.json",
    "state": "sourced",
    "value": "Netherlands"
   },
   "lei": {
    "market": "US",
    "reason": "no GLEIF record with the exact legal name in jurisdiction US-P7",
    "state": "not_on_record"
   },
   "name": {
    "read_by": "EDGAR submissions API (issuer header as filed)",
    "read_date": "2026-11-08",
    "read_date_basis": "the record version as_of",
    "source": "https://data.sec.gov/submissions/CIK0001936258.json",
    "state": "sourced",
    "value": "NewAmsterdam Pharma Co N.V."
   },
   "sector": {
    "read_by": "EDGAR submissions API (issuer header as filed) (SIC code as assigned by the SEC)",
    "read_date": "2026-11-08",
    "read_date_basis": "the record version as_of",
    "source": "https://data.sec.gov/submissions/CIK0001936258.json",
    "state": "sourced",
    "value": "2834 Pharmaceutical Preparations"
   },
   "security_type": {
    "read_by": "EDGAR submissions API (issuer header as filed)",
    "read_date": "2026-11-08",
    "read_date_basis": "the record version as_of",
    "source": "https://data.sec.gov/submissions/CIK0001936258.json",
    "state": "sourced",
    "value": "Corporate"
   },
   "segment": {
    "market": "US",
    "state": "not_on_record"
   },
   "ticker": {
    "read_by": "EDGAR company_tickers_exchange.json (SEC list of exchange-listed filers)",
    "read_date": "2026-11-08",
    "read_date_basis": "the record version as_of",
    "source": "https://www.sec.gov/files/company_tickers_exchange.json",
    "state": "sourced",
    "value": "NAMS"
   },
   "website": {
    "market": "US",
    "state": "not_on_record"
   }
  },
  "licensed": {
   "columns": [
    "licensor",
    "entitlement",
    "title",
    "date",
    "source"
   ],
   "rows": [],
   "rule": "A licensed row is served only to an agent whose firm holds that licence (licensor, entitlement). No licensed row is loaded."
  },
  "lifecycle": {
   "delisting": [],
   "domicile_change": {
    "market": "US",
    "reason": "EDGAR states no dated change of state of incorporation on a filing line",
    "state": "not_on_record"
   },
   "listing": [],
   "name_change": [],
   "segment_move": {
    "market": "US",
    "reason": "the exchanges' tier transfers are not EDGAR filings",
    "state": "not_on_record"
   }
  },
  "market": "US",
  "node": "us-cm-kg",
  "numbers_hash": "sha256:2ede10568731ce53b7b8ce5185936767fdb28e98327dae38068bfe59ddbd8df9",
  "open_research": {
   "read_date": "2026-11-11",
   "rows": [],
   "state": "none_found"
  },
  "orderability": {
   "chapter_as_of": "2026-11-04",
   "client_categories": [],
   "determinable": false,
   "read": {
    "chapter": "https://mcp.us-cm-kg.ai/book/aio.json",
    "door": "https://mcp.us-cm-kg.ai/mcp",
    "tool": "get_orderability"
   },
   "reason": "the chapter's orderability section carries no client_categories: the outcome cannot name its client category",
   "rule_version": "acm-68000/us/reasonable-basis-suitability-finra-rule-2111/r1",
   "section": "us.aio.v8"
  },
  "record": {
   "as_of": "2026-11-08",
   "url": "https://mcp.us-cm-kg.ai/record/NASDAQ/NAMS",
   "version": 1
  },
  "schema": "research-numbers v0.1 (USR-01, 2026-11-11)",
  "status": {
   "read_date": "2026-11-08",
   "source": "https://www.nasdaqtrader.com/rss.aspx?feed=tradehalts",
   "value": "listed, not halted"
  }
 },
 "numbers_hash": "sha256:2ede10568731ce53b7b8ce5185936767fdb28e98327dae38068bfe59ddbd8df9",
 "path": "/us/NASDAQ/NAMS",
 "schema": "research-page v0.1 (USR-02, 2026-11-11)",
 "sections": [
  {
   "id": "identity",
   "text": "The issuer is NewAmsterdam Pharma Co N.V., listed on NASDAQ under ticker NAMS, with ISIN USN625091095. The LEI is not on the record (no GLEIF record with the exact legal name in jurisdiction US-P7). The security type is Corporate, the segment is not on the record, the sector is 2834 Pharmaceutical Preparations, and the jurisdiction is Netherlands. The issuer is listed and not halted.",
   "title": "Identity and listing"
  },
  {
   "id": "disclosure",
   "text": "The record holds 81 filings in the twelve months from 2025-11-08 to 2026-11-08, across 53 filing days. The median gap between filing days is 4.0 days. The latest filing is dated 2026-11-05, a regulatory_filing, 3 days before the record date. The NASDAQ median for filings is 52, the median cadence gap is 6.0 days, and the median latency is 5.0 days. The sector median for filings is 63.0, the median cadence gap is 6.0 days, and the median latency is 4.0 days.",
   "title": "The disclosure read"
  },
  {
   "id": "auditor",
   "text": "The auditor is not on the record (no dei:AuditorName tag on the latest annual report cover; foreign private issuers and older filings carry none). The auditor location is not on the record. The record holds no auditor changes.",
   "title": "Auditor"
  },
  {
   "id": "events",
   "text": "The record holds no listing, delisting or name change lines. The domicile change is not on the record (EDGAR states no dated change of state of incorporation on a filing line). The segment move is not on the record (the exchanges' tier transfers are not EDGAR filings). The halt flag is listed, not halted.",
   "title": "Events and halts"
  },
  {
   "id": "orderability",
   "text": "The outcome is not determinable: the chapter's orderability section carries no client_categories, so the outcome cannot name its client category. The rule version is acm-68000/us/reasonable-basis-suitability-finra-rule-2111/r1, with the chapter as of 2026-11-04.",
   "title": "Orderability"
  },
  {
   "id": "coverage",
   "text": "The issuer's own investor-relations page names 17 research houses: BMO Capital Markets, Cantor Fitzgerald & Co., Citi, Goldman Sachs & Co. LLC, Guggenheim Securities, LLC, H.C. Wainwright, Jefferies, Leerink Partners, Needham & Company, LLC, Piper Sandler & Co, RBC Capital Markets, Stifel, TD Cowen, Truist Securities, Van Lanschot Kempen, Wells Fargo, and William Blair & Company.",
   "title": "Coverage"
  },
  {
   "id": "open_research",
   "text": "The record holds no openly published research notes. None was found.",
   "title": "Open research"
  },
  {
   "id": "licensed",
   "text": "Licensed research: none loaded. A licensed row is served only to an agent whose firm holds that licence (licensor, entitlement). No licensed row is loaded.",
   "title": "Licensed"
  },
  {
   "id": "depth",
   "text": "The issuer's years sealed are 2022, 2023, 2024, 2025 and 2026. The market's earliest sealed date is 2021-01-04. The live record began on 2026-09-12. The market's vintage is sealed.",
   "title": "As-of depth"
  },
  {
   "id": "sources",
   "text": "8 source pages are named on this page; every value above carries its own source page and read date in the numbers.",
   "title": "Sources"
  }
 ],
 "sources": [
  {
   "for": "identity.exchange",
   "source": "https://www.sec.gov/files/company_tickers_exchange.json"
  },
  {
   "for": "identity.isin",
   "source": "https://www.sec.gov/data-research/sec-markets-data/fails-deliver-data"
  },
  {
   "for": "identity.jurisdiction",
   "source": "https://data.sec.gov/submissions/CIK0001936258.json"
  },
  {
   "for": "the disclosure lines",
   "source": "https://mcp.us-cm-kg.ai/events/NASDAQ/NAMS"
  },
  {
   "for": "the halt flag",
   "source": "https://www.nasdaqtrader.com/rss.aspx?feed=tradehalts"
  },
  {
   "for": "the orderability chapter",
   "source": "https://mcp.us-cm-kg.ai/book/aio.json"
  },
  {
   "for": "coverage",
   "source": "https://ir.newamsterdampharma.com/stock-information/analyst-coverage"
  },
  {
   "for": "the record",
   "source": "https://mcp.us-cm-kg.ai/record/NASDAQ/NAMS"
  }
 ],
 "title": "NewAmsterdam Pharma Co N.V. (NAMS) — research page",
 "writer": {
  "by": "Claude through the platform account, Haiku class; one pass; checked against the numbers",
  "engine": "claude-haiku-5-5"
 }
}